Accessibility statement

Declaration on accessibility

The Federal Office for Safety in Health Care (BASG) strives to make its website accessible in accordance with the Web Accessibility Act (WZG), as amended, implementing Directive (EU) 2016/2102 of the European Parliament and of the Council of 26 October 2016 on barrier-free access to the websites and mobile applications of public sector bodies (Official Journal L 327, 2.12.2016, p. 1).

This accessibility statement applies to the website

Status of compatibility with the requirements

This website is fully compliant with compliance level AA of the "Web Accessible Content Guidelines Web - WCAG 2.1" according to the applicable harmonized European standard "European Standard EN 301 549 V2.1.2 (2018-08)".

Non-accessible contents

There is currently no known non-compliant content. During the development process, all barriers known at the time of the accessibility analysis were removed.

Note for screen reader users: The "Trade name" field for selecting the vaccine or drug is a combined input/selection list field with limited accessibility with some screen readers. We have tested different solutions for this interface component and are committed to providing the best possible user experience and accessibility.

If the list suggestions should not be directly selectable, the trade name can be entered as free text in the field as an alternative input option. This should make the field accessible to all users. If you still notice problems with the input, please contact us at the contact address below with a description of the error.

Preparation of this Accessibility Statement

This statement was created on 29 January 2021. Last updated 28 June 2021.

The assessment of the website's compliance with the WZG for the implementation of the requirements of Directive (EU) 2016/2102 was carried out through an accessibility analysis according to WCAG 2.1 compliance level AA by the external service provider Pixel Melange Ing. Jürgen Bartl ( during the website development in January 2021. The homepage as well as all form steps and functions on desktop and mobile devices were checked with additional random checks of the form validation with a screen reader. Through a quality assurance process, all accessibility issues found in the analysis were resolved. Some pages of the site link externally to the BASG website. This website was not part of the analysis.

The website underwent several enhancement steps from April to June 2021, including the addition of the following features:

  • Additional form steps for pharmacies, hospitals, ordinaries and other healthcare professionals.
  • Privacy measures, session duration display and extension option, data loss warning dialog when time expires.
  • Health professionals have the option to save reporting data for further reporting.

In this context, a re-review and WCAG evaluation was conducted and completed on June 28, 2021.

Feedback and contact details

Great attention has been paid to barrier-free design in the development of this website. Should you nevertheless notice barriers that prevent you from using our website - problems that are not described in this statement, deficiencies in terms of compliance with accessibility requirements - we ask you to report them to us at the contact below. We will review your request and contact you as soon as possible.


Enforcement proceedings

In the event of unsatisfactory responses from the above contact option, you can contact the Austrian Research Promotion Agency with limited liability (FFG) by means of a complaint. The FFG accepts complaints electronically via the contact form.

Contact form of the complaints office

The complaints are examined by the FFG to determine whether they relate to violations of the provisions of the Web Accessibility Act, in particular deficiencies in compliance with accessibility requirements, by the federal government or an institution attributable to it.

If the complaint is justified, the FFG must issue recommendations for action to the Federal Government or the legal entities concerned and propose measures to remedy the deficiencies at hand.

Further information on the complaints procedure


Further inquiry note